Pyxis Oncology's Losses Mount, Cash Dwindles Amid R&D Spend

TL;DR

**Pyxis is burning cash fast with no significant revenue, making it a high-risk bet unless they secure major funding immediately.**

AI Summary

Pyxis Oncology, Inc. reported a net loss of $61.5 million for the nine months ended September 30, 2025, a significant increase from the $41.8 million net loss for the same period in 2024. The company's total revenues decreased substantially to $2.82 million for the nine months ended September 30, 2025, compared to $16.146 million in the prior year, primarily due to the absence of royalty revenues and sale of royalty rights which contributed $8.146 million and $8.000 million respectively in 2024. Research and development expenses rose to $51.985 million for the nine months ended September 30, 2025, up from $44.723 million in 2024, reflecting ongoing clinical development. General and administrative expenses decreased to $16.960 million from $20.339 million year-over-year. As of September 30, 2025, Pyxis Oncology had cash, cash equivalents, and short-term investments totaling $76.3 million, a decrease from $126.931 million at December 31, 2024. The company explicitly stated that its current capital is insufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern.

Why It Matters

This filing reveals Pyxis Oncology's precarious financial position, with a significant increase in net loss and a sharp decline in revenue, primarily due to the absence of prior year's royalty income. For investors, the explicit 'going concern' warning is a critical red flag, indicating a high risk of dilution through future equity raises or potential operational curtailment if funding isn't secured. Employees face uncertainty regarding job security and the company's long-term viability. Customers and the broader market, particularly those interested in oncology advancements, should note that the company's ability to bring its lead product candidate, micvotabart pelidotin, to market is heavily dependent on securing additional capital, impacting competitive dynamics in the HNSCC treatment space.

Risk Assessment

Risk Level: high — The company explicitly states, "the current available cash, cash equivalents and short-term investments, will not be sufficient to fund the Company's operations over the next 12 months from the date of this Quarterly Report on Form 10-Q." This condition, coupled with an accumulated deficit of $425.1 million as of September 30, 2025, and a net loss of $61.5 million for the nine months ended September 30, 2025, indicates severe liquidity issues and a substantial doubt about its ability to continue as a going concern.

Analyst Insight

Investors should exercise extreme caution and consider divesting, as the 'going concern' warning signals imminent financial distress and potential significant dilution. New investors should avoid taking a position until the company demonstrates a clear path to securing substantial, non-dilutive funding or achieving profitability, which appears distant given its clinical stage.

Financial Highlights

debt To Equity

0.54

revenue

$2.82M

operating Margin

N/A

total Assets

$105.604M

total Debt

$36.825M

net Income

-$61.232M

eps

N/A

gross Margin

N/A

cash Position

$76.3M

revenue Growth

-82.5%

Revenue Breakdown

Key Numbers

• $61.5M — Net Loss (for the nine months ended September 30, 2025, increased from $41.8M in 2024)
• $2.82M — Total Revenues (for the nine months ended September 30, 2025, down from $16.146M in 2024)
• $51.985M — Research and Development Expenses (for the nine months ended September 30, 2025, up from $44.723M in 2024)
• $76.3M — Cash, Cash Equivalents, and Short-Term Investments (as of September 30, 2025, insufficient to fund operations for the next 12 months)
• $425.1M — Accumulated Deficit (as of September 30, 2025, indicating significant historical losses)
• 62,264,215 — Shares Outstanding (as of October 31, 2025)

Key Players & Entities

• Pyxis Oncology, Inc. (company) — registrant of the 10-Q filing
• SEC (regulator) — Securities and Exchange Commission
• Nasdaq Global Select Market (market) — exchange where PYXS common stock is registered
• micvotabart pelidotin (product) — Pyxis Oncology's lead product candidate in early clinical development
• Pfizer (company) — licensor in a critical intellectual property agreement with Pyxis Oncology
• Delaware (location) — state of incorporation for Pyxis Oncology, Inc.
• Boston, Massachusetts (location) — principal executive offices of Pyxis Oncology, Inc.
• HNSCC (medical_condition) — head and neck squamous cell carcinoma, focus of Pyxis Oncology's development strategy

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company has a substantial accumulated deficit of $425.1M as of September 30, 2025. Its current cash, cash equivalents, and short-term investments of $76.3M are insufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern.
• Declining Revenue [high — financial]: Total revenues decreased significantly to $2.82M for the nine months ended September 30, 2025, from $16.146M in the same period of 2024. This decline is primarily due to the absence of royalty revenues and sale of royalty rights.
• Increasing R&D Expenses [medium — operational]: Research and development expenses increased to $51.985M for the nine months ended September 30, 2025, from $44.723M in the prior year. This rise reflects ongoing clinical development, which requires significant capital outlay.
• Deteriorating Cash Position [high — financial]: The company's cash, cash equivalents, and short-term investments have decreased from $126.931M at December 31, 2024, to $76.3M as of September 30, 2025. This represents a reduction of over $50M in less than a year.

Industry Context

The biotechnology industry, particularly in oncology, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often rely on substantial funding rounds or strategic partnerships to advance drug candidates through clinical trials. The competitive landscape is intense, with many players vying for breakthroughs in treating various cancers.

Regulatory Implications

As a clinical-stage biotechnology company, Pyxis Oncology is subject to stringent regulatory oversight from bodies like the FDA. Delays in clinical trials, failure to meet efficacy endpoints, or manufacturing issues can have severe financial and operational consequences. The company's ability to navigate these regulatory pathways is critical for its future success.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Key Dates

• 2025-09-30: End of Nine Months Reporting Period — Key financial results for the period, including net loss, revenue, expenses, and cash position, are reported.
• 2025-12-31: Previous Year End — Provides a baseline for comparison of assets and liabilities, with cash and equivalents at $19.473M and marketable debt securities at $107.458M.
• 2024-09-30: Prior Year Nine Months Reporting Period — Shows significantly higher revenues ($16.146M) and a smaller net loss ($41.8M) compared to the current period.

Glossary

Accumulated deficit

The cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates Pyxis Oncology has incurred significant losses over its history, with a current deficit of $425.1M.)

Going concern

A business's ability to continue operating for the foreseeable future without the threat of liquidation. (Pyxis Oncology explicitly states substantial doubt about its ability to continue as a going concern due to insufficient capital.)

Marketable debt securities, short-term

Investments in debt instruments that are readily tradable in the market and expected to be converted to cash within one year. (Represents a significant portion of the company's liquid assets, totaling $67.3M as of September 30, 2025.)

Research and development expenses

Costs incurred in the process of discovering, designing, and developing new products or services. (These expenses are a major cost driver for Pyxis Oncology, increasing to $51.985M for the nine months ended September 30, 2025.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, Pyxis Oncology has experienced a dramatic decline in total revenues, falling from $16.146M to $2.82M, primarily due to the cessation of royalty-related income. While R&D expenses have increased from $44.723M to $51.985M, reflecting ongoing development, G&A expenses have decreased. The company's cash position has also significantly eroded, leading to a heightened going concern risk, a factor not as pronounced in the prior period.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share PYXS Nasdaq Global Select

Filing Documents

• pyxs-20250930.htm (10-Q) — 2534KB
• pyxs-ex31_1.htm (EX-31.1) — 16KB
• pyxs-ex31_2.htm (EX-31.2) — 16KB
• pyxs-ex32_1.htm (EX-32.1) — 10KB
• pyxs-ex32_2.htm (EX-32.2) — 9KB
• img33348496_0.jpg (GRAPHIC) — 347KB
• 0001193125-25-261696.txt ( ) — 9874KB
• pyxs-20250930.xsd (EX-101.SCH) — 1289KB
• pyxs-20250930_htm.xml (XML) — 1447KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 2 Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 2 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2025 and 2024 3 Condensed Consolidated Statements of Stockholders' Equity for the Three and Nine Months Ended September 30, 2025 and 2024 4 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 5 Notes to Condensed Consolidated Financial Statements 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 26 Item 4.

Controls and Procedures

Controls and Procedures 26 PART II. OTHER INFORMATION 28 Item 1.

Legal Proceedings

Legal Proceedings 28 Item 1A.

Risk Factors

Risk Factors 28 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 64 Item 3. Defaults Upon Senior Securities 64 Item 4. Mine Safety Disclosures 64 Item 5. Other Information 64 Item 6. Exhibits 65

Signatures

Signatures 66 i SUMMA RY RISK FACTORS You should consider carefully the risks described under "Risk Factors" in Part II, Item 1A of this Quarterly Report on Form 10-Q. References to "Pyxis Oncology," the "Company," "we," "us," and "our" in this section titled "Summary Risk Factors" refer to Pyxis Oncology, Inc. and its wholly owned subsidiaries. A summary of the risks that could materially and adversely affect our business, financial condition, operating results and prospects include the following: We are a clinical stage oncology company with a limited operating history and have incurred significant losses since our inception and anticipate that we will continue to incur losses over at least the next several years and may never achieve or maintain profitability. We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce or eliminate one or more of our research and product development programs or future commercialization efforts. We are heavily dependent on the success of our product candidate, micvotabart pelidotin, which is in the early stages of clinical development. If our product candidate is not successful in clinical trials or does not receive regulatory approval or licensure or is not successfully commercialized, our business will be materially and adversely affected. Our product candidate may fail in development or suffer delays that materially and adversely affect its commercial viability. If we or our existing or future collaborators are unable to initiate and complete clinical development of, obtain regulatory approval or licensure for or commercialize our product candidate or experience significant delays in doing so, our business will be materially harmed. Our product candidate may cause undesirable and unforeseen side effects or have other properties impacting safety that could halt its clinical development, de

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. PYXIS ONCOLO GY, INC. Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts) (Unaudited) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 8,919 $ 19,473 Marketable debt securities, short-term 67,337 107,458 Restricted cash 1,472 1,472 Prepaid expenses and other current assets 5,345 4,037 Total current assets 83,073 132,440 Property and equipment, net 8,460 9,899 Intangible assets, net 2,434 2,600 Operating lease right-of-use asset 11,637 12,242 Total assets $ 105,604 $ 157,181 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 9,756 $ 4,859 Accrued expenses and other current liabilities 7,996 11,371 Operating lease liabilities, current portion 1,630 1,450 Total current liabilities 19,382 17,680 Operating lease liabilities, net of current portion 17,400 18,650 Financing lease liabilities, net of current portion 43 100 Total liabilities 36,825 36,430 Commitments and contingencies (Note 13) Stockholders' equity: Preferred stock, par value $ 0.001 per share, 10,000,000 shares authorized; zero shares issued and outstanding — — Common stock, $ 0.001 par value per share; 190,000,000 shares authorized; 62,149,664 and 59,967,814 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively. 62 60 Additional paid-in capital 493,719 484,077 Accumulated other comprehensive income 69 170 Accumulated deficit ( 425,071 ) ( 363,556 ) Total stockholders' equity 68,779 120,751 Total liabilities and stockholders' equity $ 105,604 $ 157,181 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 2 PYXIS ONCOLOGY, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (In